Literature DB >> 3997857

Protease nexin. Properties and a modified purification procedure.

R W Scott, B L Bergman, A Bajpai, R T Hersh, H Rodriguez, B N Jones, C Barreda, S Watts, J B Baker.   

Abstract

The present paper describes chemical and functional properties of protease nexin, a serine protease inhibitor released from cultured human fibroblasts. It is shown that protease nexin is actually synthesized by fibroblasts and represents about 1% of their secreted protein. Analysis of the amino acid composition of purified protease nexin indicates that it is evolutionarily related to antithrombin III and heparin cofactor II. Protease nexin contains approximately 6% carbohydrate, with 2.3% amino sugar, 1.1% neutral sugar, and 3.0% sialic acid. The Mr calculated from equilibrium sedimentation analysis is 43,000. Protease nexin is a broad specificity inhibitor of trypsin-like serine proteases. It reacts rapidly with trypsin (kassoc = 4.2 +/- 0.4 X 10(6) M-1 s-1), thrombin (kassoc = 6.0 +/- 1.3 X 10(5) M-1 s-1), urokinase (kassoc = 1.5 +/- 0.1 X 10(5) M-1 s-1), and plasmin (kassoc = 1.3 +/- 0.1 X 10(5) M-1 s-1), and slowly inhibits Factor Xa and the gamma subunit of nerve growth factor but does not inhibit chymotrypsin-like proteases or leukocyte elastase. In the presence of heparin, protease nexin inhibits thrombin at a nearly diffusion-controlled rate. Two heparin affinity classes of protease nexin can be detected. The present characterization pertains to the fraction of protease nexin having the higher affinity for heparin. The low affinity material, which is the minor fraction, is lost during purification.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3997857

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  53 in total

Review 1.  Regulation of renal sodium handling through the interaction between serine proteases and serine protease inhibitors.

Authors:  Kenichiro Kitamura; Kimio Tomita
Journal:  Clin Exp Nephrol       Date:  2010-06-11       Impact factor: 2.801

2.  Protease nexin-1, an antithrombin with neurite outgrowth activity, is reduced in Alzheimer disease.

Authors:  S L Wagner; J W Geddes; C W Cotman; A L Lau; D Gurwitz; P J Isackson; D D Cunningham
Journal:  Proc Natl Acad Sci U S A       Date:  1989-11       Impact factor: 11.205

3.  Protease nexin-1, tPA, and PAI-1 are upregulated in cryoglobulinemic membranoproliferative glomerulonephritis.

Authors:  Sekiko Taneda; Kelly L Hudkins; Anja S Mühlfeld; Jolanta Kowalewska; Jeffrey W Pippin; Stuart J Shankland; Charles E Alpers
Journal:  J Am Soc Nephrol       Date:  2008-01-16       Impact factor: 10.121

4.  A simple two-step purification of protease nexin.

Authors:  D H Farrell; W E Van Nostrand; D D Cunningham
Journal:  Biochem J       Date:  1986-08-01       Impact factor: 3.857

5.  A potential role for protease nexin 1 overexpression in the pathogenesis of scleroderma.

Authors:  D Strehlow; A Jelaska; K Strehlow; J H Korn
Journal:  J Clin Invest       Date:  1999-04       Impact factor: 14.808

6.  The serine protease inhibitor serpinE2 is a novel target of ERK signaling involved in human colorectal tumorigenesis.

Authors:  Sébastien Bergeron; Etienne Lemieux; Véronique Durand; Sébastien Cagnol; Julie C Carrier; Jacques G Lussier; Marie-Josée Boucher; Nathalie Rivard
Journal:  Mol Cancer       Date:  2010-10-13       Impact factor: 27.401

7.  Polymorphism of SERPINE2 gene is associated with pulmonary emphysema in consecutive autopsy cases.

Authors:  Koichi Fujimoto; Shinobu Ikeda; Tomio Arai; Noriko Tanaka; Toshio Kumasaka; Takeo Ishii; Kozui Kida; Masaaki Muramatsu; Motoji Sawabe
Journal:  BMC Med Genet       Date:  2010-11-10       Impact factor: 2.103

8.  SERPINE2, an inhibitor of plasminogen activators, is highly expressed in the human endometrium during the secretory phase.

Authors:  Robert Kuo-Kuang Lee; Chi-Chen Fan; Yuh-Ming Hwu; Chung-Hao Lu; Ming-Huei Lin; Ying-Jie Chen; Sheng-Hsiang Li
Journal:  Reprod Biol Endocrinol       Date:  2011-03-23       Impact factor: 5.211

9.  SERPINE2 polymorphisms and chronic obstructive pulmonary disease.

Authors:  Seung Ick Cha; Hyo-Gyoung Kang; Jin Eun Choi; Min Jung Kim; Jaeho Park; Won Kee Lee; Chang Ho Kim; Tae Hoon Jung; Jae Yong Park
Journal:  J Korean Med Sci       Date:  2009-11-09       Impact factor: 2.153

10.  Chronic obstructive pulmonary disease: towards pharmacogenetics.

Authors:  Alice M Wood; See Ling Tan; Robert A Stockley
Journal:  Genome Med       Date:  2009-11-30       Impact factor: 11.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.